Tag Archives: author

Cancer Immunotherapy ETF Takes Curious Approach To Asset Allocation

Summary The Loncar Cancer Immunotherapy ETF was launched recently with the goal of targeting companies actively engaged in the treatment of cancer through immunotherapy. The fund’s investment in both healthcare mega-caps and biotech small-caps provide very different exposure to immunotherapy treatments. This fund looks more like a broader healthcare ETF than a pure play on cancer immunotherapy. The ETF world is becoming increasingly niche oriented lately and another niche ETF – the Loncar Cancer Immunotherapy ETF (NASDAQ: CNCR ) – recently joined the fray. Biotech has been a popular place to create a new product lately as ETFs targeting companies involved in genomics, drugs in late stage clinical trials and medical breakthroughs have all hit the market in the past 12 months. According to the fund’s fact sheet, the Cancer Immunotherapy ETF “is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.” It charges an expense ratio of 0.79% and equal weights the portfolio among 30 holdings. How it chooses those 30 holdings is what makes it curious. The fund commits around one third of its assets to some of the world’s biggest pharmaceutical companies that are developing immunotherapy treatment technologies. The remaining two thirds of assets are invested in biotechs that develop their own immunotherapy drugs and treatments. A look at the top holdings of the ETF shows a literal who’s who of the biggest healthcare companies in the world – Celgene (NASDAQ: CELG ), Pfizer (NYSE: PFE ), Amgen (NASDAQ: AMGN ) and Merck (NYSE: MRK ). As a result of the fund’s investment objective and stock selections, the ETF is one third invested in large- and mega-cap stocks and two thirds invested in small- and micro-cap stocks. The portfolio allocation and investing style suggests to me that this fund is more healthcare ETF and less cancer immunotherapy ETF. The mega-cap pharma companies in the portfolio may have cancer immunotherapy as part of their broad corporate strategy but by no means are these companies a pure play on this technology. Even the biotechs that are selected for inclusion in the portfolio have a somewhat low bar for what qualifies them for having exposure to cancer immunotherapy. As would be expected, these companies can have drugs in the pipeline whether they’re in later stage clinical trial or just starting out in the trial phase. But they also qualify if they have something as simple as a partnership with another company to work on developing immunotherapy treatment in the future. The fund’s portfolio makes it difficult to properly categorize this ETF. Its biotech allocation makes it a risky venture since many of these small companies may live or die on the success of a single drug. The significant exposure to the biggest pharmaceutical companies helps limit overall portfolio risk but provides little direct exposure to cancer immunotherapy since they have such broad, developed and diversified drug portfolios. Conclusion Investors looking for a pure play on cancer immunotherapy treatment technologies will likely be disappointed. The mega-cap presence in the portfolio provides a degree of safety for the fund but it also dilutes the exposure to immunotherapy. While many of the biotech holdings employ cancer treatment as a primary goal, there are a handful that have a more diversified drug pipeline further affecting the direct immunotherapy exposure. Individuals looking for more of a broad healthcare and biotech investment may find this choice in the ETF space intriguing but the level of direct exposure to cancer immunotherapy treatments makes this fund less than a pure play.

Fundamental Items Rarely Affect Valuation

By Rupert Hargreaves Almost all fundamental investors based their research, analysis and investment decisions on the assumption that some positive relationships exist over time between equity valuation and key financial metrics. However, while a large amount of investment activity is based on the assumed relationships between the aforementioned factors, research conducted by S&P Capital IQ, shows that for the past decade it has been impossible to prove a strong statistical relationship between commonly referenced fundamental financial statistics and the direction of the equity market, momentum, and valuation: “Whether we are looking at various measures of profit margin, reported revenue and earnings growth, or even estimated future sales and earnings growth, the past decade’s correlations between price-to-earnings (P/E) valuations and a variety of commonly referenced fundamental financial statistics randomly range between strongly positive and negative readings.” – S&P Capital IQ Global Markets Intelligence Valuation versus fundamental data items Any investor that’s been watching the market for more than a year or two will know that the relationship between the valuation assigned to equities by stock market investors and underlying fundamental characteristics, over time, is extremely complex. There are many internal (stock specific) and external factors that can affect valuations. According to S&P Capital IQ ‘s research on the matter, the only net positive correlation relationship with P/E multiples since 2005 is related to selling, general, and administrative expense margins or the ratio of non-price of goods sold expenses to revenues. The best way to explain this relationship is with a table. (click to enlarge) P/E Valuation vs. Fundamental Data Items Based on a decade’s worth of data, S&P Capital’s research shows that a change in a company’s selling, general, and administrative expense margin is the only factor that will consistently impact earnings multiples across sectors. There is a clear reason for this correlation. Higher expenses will compress profit margins, weigh on profit and ultimately investors will abandon the company, driving the P/E lower. However, it’s unclear why a similar relationship doesn’t exist across other fundamental metrics. Prime example The tech sector is a prime example of an industry where the average P/E does not reflect the underlying and improving fundamentals. After the tech stock market bubble burst in 2000, the S&P 500 technology sector entered the economic recovery cycle in the first quarter of 2002 with a forward 12-month P/E valuation ratio of 54x. Between 2002 and 2010, tech sector valuations continued to be consistently marked down, although, the sector’s earnings growth averaged 23% per quarter throughout the period. The sector’s forward P/E reached a low watermark of 10.7 during Q3 2011 and has only recently started to readjust higher – as shown below. (click to enlarge) Interesting trends Aside from the obvious disconnect between P/E multiples and underlying fundamentals, S&P Capital IQ’s data highlights some other interesting trends. For example, the energy sector is currently trading at a forward P/E multiple of 33, exceeding the levels recorded while exiting the 2001 recession. The energy sector exited the 2001 recession with an elevated forward P/E of 24 that steadily declined to 8.6 by Q4 2005, well into the economic recovery and actually half way through the Fed’s tightening cycle, which took place between June 2004 and June 2006. The sector’s P/E bottomed in 2005, steadily increasing as the price of crude oil continued to rise from $50-$60 per barrel in the final quarter of 2005 to as high as $145 in July 2008. The sector P/E reached a peak of 15.3 in Q4 2008. These historic trends show that the current extreme forward energy sector P/E ratio reflects severely depressed anticipated future earnings per share relative to existing share prices, not unlike the excessive valuations seen at the tail-end of the tech stock market bubble in 2000. The excessive valuation now needs to be worked off as revenue and profit growth slowly becomes aligned with market pricing. The consumer discretionary sector illustrates more contemporary equity market valuation-related issues. Specifically, between mid-year 2004 and mid-year 2006, as the Fed continued to raise short-term interest rates at every Federal Open Market Committee meeting, investors became more cautious toward the consumer discretionary sector, pushing the sector’s P/E multiple down to 18.4 in the second quarter of 2006, from 19.4. Over the same period, sector earnings grew at an average of 8.8%: “Moving ahead to current valuations, the consumer discretionary sector’s forward P/E ratio has averaged 19.1x in the past two years while sector earnings per share growth has averaged 10.5%. Interestingly enough, this figure is close to the average P/E of 19.4x recorded by the sector during the prior period of Fed tightening when earnings grew by 8.8%. From this perspective, investors appear to be comfortable with a prospective Fed tightening cycle, as they were during most of the prior tightening cycle, as long as consumer discretionary sector earnings continue to grow at a healthy pace.” – S&P Capital IQ Global Markets Intelligence

Paris Attack Put These Sector ETFs In Watch

Friday the thirteenth made itself literal in Paris when it encountered the worst terror attack in Europe in over a decade. A chain of Islamic State-backed terrorist attacks killed around 130 people in the city and left hundreds injured that night. As a payback and pledge to establish a terror-free world, France launched several air raids and bombed Islamic State targets – especially in Raqqa – in Syria. This was the most hostile anti-terrorism strike by France against this Islamic group ISIS. As expected, the entire risk-pro global investing backdrop took a beating after the annihilation and is yet to return to its prior shape. However, among all asset classes and sectors, there are a few which stand to gain from this horrible incident, while other are likely to be badly hit. Below we highlight some sectors which are in focus after the Paris attack. Defense The defense sector should benefit from France’s retaliation to ISIS in Syria. Along with the terror-stricken France, several of its western allies shared this mission. Washington has strengthened its strikes in ISIS-heavy regions and destroyed 116 ISIS oil trucks in Eastern Syria. Russia also joined hands with the West, probably to show vengeance against its plane crash in Egypt. The Islamic State of Iraq and the Levant’s Sinai Branch had taken responsibility of this incident. Defense stocks gained post Paris attack on November 13 and might see further expansion as such geo-political risks are favorable for weapon manufacturers and defense contractors. In any case, defense stocks have tested all-time highs ever since the ‘ rise of Islamic State in Iraq and Syria.’ Since the major global superpowers are likely to pursue an combined attack against ISIS militants, investors should watch aerospace and deference ETFs, namely iShares US Aerospace and Defense ETF (NYSEARCA: ITA ), SPDR S&P Aerospace & Defense ETF (NYSEARCA: XAR ) and PowerShares Aerospace & Defense Portfolio (NYSEARCA: PPA ) for gains. Cyber Security Cyber security is a red hot area at present. While technology has been a great boon to mankind, it has lugged with it the ills of ‘cyber-crime’. Enterprises and government agencies constantly face cyber-attacks and are always in the want of rigorous cyber security to keep hackers at bay. Several government databases store susceptible national information that should be kept safe from terrorist invasion. After the serial Paris assault avoided the eye of national intelligence, the need for enhanced security both online or offline has become a prerequisite. In fact, the topic trending the most now is whether governments should have access to technology that preserves the confidentiality of people’s ‘communications and transactions’, for the sake of national security . Needless to say, these talks would put cyber security stocks and the related ETFs, namely PureFunds ISE Cyber Security ETF (NYSEARCA: HACK ) and First Trust NASDAQ CEA Cybersecurity ETF (NASDAQ: CIBR ) in focus in the coming days. Hospitality Since tourism and hospitality sectors are hit hard when a terror attack takes place in a certain place, France will also bear the same fate. Not only France, big American and European cities which are basically the soft targets of ISIS might see a fallback in their tourism and hotel industry. Notably, the tourist industry accounts for about 8% of the French economy. Thanks to this fear for tourism, already big U.S.-based hotel chains that have considerable exposure in Europe as well, witnessed a retreat in their share prices. Starwood Hotels & Resorts Worldwide Inc. (NYSE: HOT ), Marriott International Inc. (NASDAQ: MAR ), Hyatt Hotels Corporation (NYSE: H ) and Wyndham Worldwide Corporation (NYSE: WYN ) lost about 7%, 5%, 3.6% and 5%, respectively, in the last five days (As of November 17, 2015). Not only hotels, since travelers are likely to abandon cruise trips, the apprehensive stocks of Carnival Corporation (NYSE: CCL ) and Royal Caribbean Cruises Ltd. (NYSE: RCL ) shed about 5% each in the last five trading sessions. Notably, consumer discretionary ETF PowerShares DWA Consumer Cyclicals Momentum Portfolio (NYSEARCA: PEZ ) invests over 25% in Hotels, Restaurants & Leisure and over 11% in Airlines, while another product PowerShares Dynamic Leisure and Entertainment Portfolio (NYSEARCA: PEJ ) invests about 5% each in Carnival and the online travel company Expedia (NASDAQ: EXPE ), and about over 10% in two airlines. Investors might thus view these two ETFs for potential losses. Airlines Needless to say, lower tourism means lower air travel. Though the impact of the attack is likely to be short-lived, travelers might take some more time to get back to their previous euphoria, shrugging off all fears. The Russian plane crash in October also point to this fact. The pure play Airline ETF U.S. GLOBAL JETS ETF (NYSEARCA: JETS ) could thus see losses in the coming days. JETS lost over 2.6% in the last five days (as of November 17, 2015). Original Post